Point Biopharma has received a materials license from the U.S. Nuclear Regulatory Commission (NRC) for its new radioligand manufacturing facility in Indianapolis, IN.
The license authorizes the radiopharmaceutical company to begin handling nuclear material at the 80,000-sq-ft facility, which is almost completely renovated. The license enables Point to begin working onsite with radioisotopes such as lutetium-177 and actinium-225 and complete testing and qualification of the facility.
